444 results on '"Kuball, J"'
Search Results
2. Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit
3. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
4. Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey
5. Identification of a tumor-specific allo-HLA–restricted γδTCR
6. Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey
7. Cardio-oncology: an overview on outpatient management and future developments
8. Strategies to improve γδTCRs engineered T-cell therapies for the treatment of solid malignancies
9. Clinical versus histological grading in the assessment of cutaneous graft versus host disease
10. Strategies to improve gdTCRs engineered T-cell therapies for the treatment of solid malignancies.
11. In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review
12. Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT)
13. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio
14. CAR-T cells: the narrow path between hope and bankruptcy?
15. JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement
16. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
17. P957: CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE FOLLOWED BY A SECOND AUTO-HCT IS AN EFFECTIVE STRATEGY IN FIRST RELAPSE MULTIPLE MYELOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT
18. P1444: IMPACT OF CO-MORBIDITIES ON NON-RELAPSE MORTALITY AND CYTOKINE-RELEASE SYNDROME AFTER CD19 CAR-T CELL THERAPY - A RETROSPECTIVE STUDY FROM THE TCWP OF THE EBMT AND GOCART COALITION
19. P1382: RUXOLITINIB USE IN A REAL WORLD ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE COHORT IN THE NETHERLANDS: A RETROSPECTIVE STUDY
20. Targeting Acute Leukemia and Cancer by High-Affinity T-Cell-Receptor Transfer
21. Management of adults and children receiving CAR T- cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
22. Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells
23. Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group–an observational analysis by the Acute Leukemia Working Party of the EBMT
24. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years
25. Physiochemical disparity of mismatched HLA class I alloantigens and risk of acute GVHD following HSCT
26. The circulating platelet count is not dictated by the liver, but may be determined in part by the bone marrow: analyses from human liver and stem cell transplantations
27. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors
28. Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
29. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients : a position statement from an international expert group
30. Activity of ex vivo graft and DLI Engineering within the last decade increases, a survey from the EBMT Cellular Therapy & Immunobiology Working Party
31. Hunting for clinical translation with innate-like immune cells and their receptors
32. Hematopoietic stem cell transplantation in Europe 2014: more than 40000 transplants annually
33. Individualized stem cell donor requests: Not longer a search in a haystack: AB74
34. Beneficial role of CD8+T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias
35. Jon van Rood (1926–2017)
36. γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia
37. The impact of frequent HLA haplotypes in high linkage disequilibrium on donor search and clinical outcome after unrelated haematopoietic SCT
38. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
39. Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0)
40. The Programmed Death (PD)‐1/PD‐Ligand 1 Pathway Regulates Graft‐Versus‐Host‐Reactive CD8 T Cells After Liver Transplantation
41. AN ALTERNATIVE EXPLANATION FOR NON-PERMISSIBLE HLA-DPB1 MISMATCHES IN HEMATOPOIETIC STEM-CELL TRANSPLANTATION: HLA-DPB1-DERIVED PIRCHES CORRELATE TO ACUTE GVHD: PH-AB178
42. ANTI-CD20 THERAPY IN COMBINATION WITH NILOTINIB FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE: PH-P405
43. FEASIBILITY OF ALPHA BETA T- CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATIONS FROM MATCHED RELATED AND UNRELATED DONOR GRAFTS AND ENGRAFTMENT IN PATIENTS WITH POOR RISK LEUKEMIA: PH-P110
44. CONDITIONING INTENSITY IN MIDDLE AGED PATIENTS WITH AML IN CR1. NO ADVANTAGE FOR MYELOABLATIVE REGIMENS IRRESPECTIVE OF THE RISK GROUP. AN OBSERVATIONAL ANALYSIS BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT: PH-O148
45. TREATMENT OF STEROID RESISTANT GRADE II TO IV ACUTE GVHD BY INFUSION OF MESENCHYMAL STROMA CELLS EXPANDED WITH PLATELET LYSATE - A PHASE I/II STUDY: PH-O035
46. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
47. Identification of a tumor-specific allo-HLA-restricted gamma delta TCR
48. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
49. Schmerzerfassung bei invasiven diagnostischen Prozeduren: Vergleich einer elfstufigen numerischen Rangskala und einer sechsstufigen verbalen Kategorialskala zur Schmerzmessung bei Knochenmarkpunktion
50. г-δ T-cells elicited by CMV-reactivation after allo-SCT crossrecognize CMV and leukaemia: O397
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.